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Abstract 
Chikungunya virus is a re-emerging arbovirus transmitted to humans by mosquitoes, responsible for an 
acute flu-like illness associated with debilitating arthralgia, which can persist for several months or 
become chronic. In recent years, this viral infection has spread worldwide with a previously unknown 
virulence. To date, no specific antivirals treatments nor vaccines are available against this important 
pathogen. Starting from the structures of two antiviral hits previously identified in our research group 
with in silico techniques, this work describes the design and preparation of 31 novel structural analogues, 
with which different pharmacophoric features of the two hits have been explored and correlated with the 
inhibition of Chikungunya virus replication in cells. Structure-activity relationships were elucidated for 
the original scaffolds, and different novel antiviral compounds with EC50 values in the low micromolar 
range were identified. This work provides the foundation for further investigation of these promising 
novel structures as antiviral agents against Chikungunya virus. 
 
1. Introduction 
Chikungunya virus (CHIKV) is an Arbovirus that belongs to the Alphavirus genus of the Togaviridae 
family. Transmitted to humans by mosquito Aedes Aegypti, it is associated with an acute pathology 
characterised by fever, rash and arthralgia. The last condition is often severe and may persist for several 
months or become chronic in the 10% of infected individuals.1 CHIKV infection was first described in 
Tanzania in 1952 and since 2005 it re-emerged with a previously unknown virulence in Africa, Indian 
Ocean, India and South-East Asia, reaching Europe and the US.2-3 The ability to adapt to a new vector, 
the mosquito Aedes Albopictus, has contributed to the worldwide spread of the infection.4 Clinically 
approved compounds such as chloroquine, alpha-interferon and ribavirin, even if showing some antiviral 
effect in vitro, demonstrated poor in vivo activity against CHIKV infection and, to date, no specific 
treatment is available, nor a vaccine is approved: the therapy is still limited to supportive treatment of 
the symptoms.5-6 Research interest on CHIKV has been rapidly increasing in the last few years. However, 
to date, only few selective anti-CHIKV agents have been reported, and none of them has reached the 
clinical evaluation stage.7 
As part of an ongoing project aiming to identify novel inhibitors of Chikungunya virus replication, the 
structures of our previous hits 1 and 2 (Figure 1), identified as inhibitors of the CHIKV life cycle 
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following a docking-based virtual screening analysis of commercial compounds on the structure of the 
viral nsP2 protease,8 have been modified to gain insights into the antiviral structure-activity relationships 
associated with this molecular scaffold. These novel structural modifications led to a deeper 
understanding of the pharmacophoric features required for antiviral activity and to the identification of 
novel anti-CHIKV agents with antiviral EC50 values in the low micromolar range and good selectivity 
indexes. 
 
2. Results and discussion 
 
2.1 Rational design of novel analogues 
The scaffold of hits 1 and 2 is characterised by the presence of two differently substituted phenyl rings, 
ring A and ring B, a hydrazyde group directly attached to ring B, and an aliphatic spacer (a cyclopropyl 
group in the trans configuration or a trans double bond) connecting ring A with the central hydrazyde 
function. In order to further explore the antiviral structure-activity relationships associated with these 
agents, and taking into account our previously reported preliminary explorations of their structures,8 a 
series of 31 novel molecular analogues was designed and synthesised. As summarised in Figure 1, 
several new modifications to the original structures were carried out in order to: 1. explore different 
aromatic substituents on the two phenyl rings, while maintaining a central linker characterised by a 
cyclopropyl group in the trans configuration or a trans double bond linked to a hydrazide feature; 2. 
replace the original hydrazide with a more stable amide function; 3. investigate the role of the rigidity of 
the central linker by reducing the trans-double bond to an ethyl group. 
 
Figure 1. Structure of our previous antiviral hits and their proposed modifications. 
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With the aim to take into account and to further confirm our previously reported structural 
considerations,8 the novel analogues were designed to either maintain a hydrophobic substituent (tert-
butyl or methyl) in the para position of aromatic ring A, or to remove completely this substituent, in order 
to assess its essential role for antiviral activity. The nature and presence of the two original ethoxy groups 
in aromatic ring B was also extensively explored to understand their role in the inhibition of the viral 
replication. Due to the easier purification associated with the presence of a trans double bond replacing 
the trans-cyclopropilic ring of the original hit, and to the fact that 2 is not associated with any cytotoxic 
effect in vitro,8 most of the planned modifications on the two aromatic systems were carried out on the 
trans-ethylidene scaffold of 2.  As a first attempt to improve the stability of 2, which is not predicted to 
be highly stable in aqueous conditions due to the presence of a hydrazone function, a small series of 
novel analogues was envisaged to replace this group with a more stable amide bond. In the case of this 
last modification, in order to partially compensate for the reduced overall length of the molecule, which 
appears to be detrimental for antiviral activity according to our previous preliminary SAR data obtained 
for the original scaffold 1,8 the insertion of an amide linker was only attempted with a bi-phenyl system 
replacing ring B, or with a para-trifluoromethyl substituent on aromatic ring B. 
 
2.2 Chemistry 
All target compounds were synthesised according to an optimised two to four-step synthetic pathway, as 
shown in Schemes 1-3. 
 
 
Scheme 1: Reagents and conditions: i. ethyldiazoacetate, 125 °C, 4 h, r.t., o.n. (45%); hydrazine monohydrate, EtOH, reflux, o.n. 
(85%); differently substituted benzaldehyde, EtOH, reflux, 24 h (54-76%). 
 
Following our previously reported procedure,8 a small series of novel cyclopropyl derivatives was 
prepared  by reaction of 4-tert-butyl styrene with ethyldiazoacetate at 125 °C for 4h, followed by stirring 
at r.t. o.n. In these conditions, a mixture of the two disatereomeric couples of enantiomers at the 
cyclopropane ring is obtained (cis and trans), and the desired pure trans-substituted intermediate 4 was 
isolated after chromatographic purification in a mixture of dichloromethane and diethyl ether. Ester 4 
was then refluxed in EtOH with an excess of hydrazine monohydrate to yield hydrazide 5, which was 
then treated with the appropriate differently substituted benzaldehyde to afford final hydrazones 6 and 7. 
These final products were envisaged to further investigate our previous findings suggesting that a 
hydroxyl group in the para position of aromatic ring B is tolerated by its introduction together with the 
tert-butyl substituent in ring A (7) and by its alkylation to methyl ether (6). 
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Scheme 2: Reagents and conditions: i. malonic acid, cat. piperidine, pyridine, r.t., 3h (93-98%); ii. (a) oxalyl chloride, Et2O, r.t., 
3 h, (b) hydrazine monohydrate, r.t., 2 h (50-63%); iii. differently substituted benzaldehyde, EtOH, reflux, 24 h (65-77%); iv. 
differently substituted benzylamine, TBTU, diisopropylethylamine, anhydrous DMF, r.t., o.n. (83-96%). 
 
A series of 17 novel benzylidene-acrylohydrazides was instead prepared to further explore the effect of 
the aromatic substituents on aromatic rings A and B on the scaffold of 2. Cinnamic acids 9a-c were 
prepared following a Knoevenagel condensation- Doebner modification reaction between aldehydes 8a-
c and malonic acid, in the presence of catalytic amounts of piperidine and refluxing the mixture in 
pyridine. 9 Acid intermediates 9a-c were then converted to the corresponding acyl chlorides using oxalyl 
chloride,10 and treated in situ with hydrazine monohydrate to give acrylo-hydrazides 10a-c,11 which were 
finally reacted with differently substituted benzaldehydes or acetophenones to give target compounds 
11-24.12 Starting from intermediate acids 9a and 9c, a small family of 4 novel acrylamide analogues was 
obtained following a TBTU-assisted coupling reaction with differently substituted benzylamines in the 
presence of diisopropylamine.13 This last modification was envisaged as a means to replace the 
hydrazone function on the final products with a more stable amide group. Due to the overall reduced 
length of the scaffold, and according to some preliminary results obtained for the corresponding amide 
product with a 3,4-dimethoxy substituent on aromatic ring B,8 this structural change from hydrazone to 
amide was envisaged together with the insertion of a biphenyl system to replace ring B (26a, c). 25a and 
25c were prepared to compare the effect of the second phenyl ring with a smaller hydrophobic group, 
namely the trifluoromethyl. 
 
 
Scheme 3: Reagents and conditions: i. H2, 10% Pd/C, THF, r.t., 4h (93-98%); ii. (a) 1.25 M HCl in MeOH, reflux, o.n., (b) 
hydrazine monohydrate, EtOH, reflux, o.n. (65-67%); differently substituted benzaldehyde, EtOH, reflux, 24 h (73-95%). 
 
As a first attempt to investigate the role of the rigidity of the original linker (trans-cyclopropylhydrazide 
or acrylohydrazide), a small family of 8 novel analogues was designed to replace the two rigid systems 
in the original hits with a reduced ethyl group connecting aromatic ring A with the hydrazide portion of 
the scaffold. The desired modification was achieved by catalytic hydrogenation of cinnamic acids 9a and 
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9c to their unsaturated counterparts 27a and 27c, performed under H2 atmosphere in the presence of 10% 
Pd/C catalyst.14 The unsaturated acid intermediates 27a, c were then converted to their methyl ester 
counterparts by refluxing in 1.25M HCl in methanol, and subsequently treated with hydrazine 
monohydrate in boiling EtOH to achieve the desired ester displacement in hydrazides 28a, c.15 Final 
compounds 29-32 were obtained as reported for the other two series of hydrazone compounds, by 
reacting hydrazides 28a, c with the appropriately substituted benzaldehyde or acetophenone in refluxing 
EtOH for 24 hours. 
 
2.3 Antiviral and cytotoxicity studies 
All the newly synthesised compounds were evaluated for their potential anti-CHIKV activity in Vero 
cells, investigating their ability to inhibit the cytopathogenic effect (CPE) induced by the virus, and for 
their potential cytotoxicity. The known anti-CHIKV agent Chloroquine was included as positive 
control.16 
 
Table 1: Antiviral effect of the test compounds on CHIKV replication in Vero cells and cytotoxicity. 
 
Comp. Scaffold R1 
(ring A) 
R2 Ar 
(ring B) 
EC
50
(M)a,d EC
90
(M)b,d CC
50
(M)c,d SIe 
1af a t-Bu H 3,4-OEt-Ph 5.0±0.2 6.4±0.5 72±20 14 
1bf a t-Bu H 4-CF3-Ph 14±6 19±10 30±5 2.1 
1cf a H H 4-OH-Ph 6.4±0.1 8.7±0.2 15±1 2.3 
1df a H Me 4-C6H11-Ph 32±1 44±1 101±1 3.1 
1ef a H Me 4-OMe-Ph 5.6±2 12±6 72±2 13 
2f b t-Bu H 3,4-OEt-Ph 3.2±1.8 11±4 101±50 32 
6 a t-Bu H 4-Me-Ph 6.6 n.d. n.d. - 
7 a t-Bu H 4-OH-Ph 2.7 3.8 n.d. - 
11a b t-Bu H 4-OMe-Ph 5.9±0.8 38.8±16.4 117±23.8 19.8 
12a b t-Bu H 4-Me-Ph 5.8±0.9 10±3.4 124±7.1 21.4 
12b b Me H 4-Me-Ph >359 >359 n.d. - 
12c b H H 4-Me-Ph 93.3 >284 84.4±11.5 0.9 
13a b t-Bu H 4-iPr-Ph 2.1±2.4 n.d. 7.4±0.6 3.5 
14a b t-Bu H t-Bu-Ph >276 >276 n.d. - 
15a b t-Bu Me 4-C6H11-Ph >248 >248 n.d. - 
15c b H Me 4-C6H11-Ph >289 >289 n.d. - 
16a b t-Bu H Ph 5.8±1.4 87.5±79.1 22.1±6.8 3.8 
17a b t-Bu H 4-NO2-Ph >285 >285 n.d. - 
18a b t-Bu Me 4-Cl-Ph >282 >282 n.d. - 
19a b t-Bu H 4-OH-Ph n.d. n.d. 7.3±1.9 - 
20a b t-Bu Me Pyrazine 103 122±32.1 >310 1.2 
21a b t-Bu Me 3,4-OMe-Ph >263 >263 n.d. - 
22a b t-Bu H 4-Ph-Ph n.d. n.d. 20.1±12.6 - 
23a b t-Bu Me 4-Ph-Ph >252 >252 n.d. - 
24b b Me H 3,4-OEt-Ph 113 >284 >284 >2.5 
25a d t-Bu CF3 - 125±91.1 47.9 115±11 0.9 
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25c d H CF3 - >246 >246 n.d. - 
26a d t-Bu Ph - 2.9 >271 4.3±1.1 - 
26c d H Ph - >319 >319 n.d. - 
29a c t-Bu H 3,4-OEt-Ph >11 >11 n.d. - 
29c c H H 3,4-OEt-Ph >294 >294 n.d. - 
30a c t-Bu H 4-Me-Ph >100 >100 n.d. - 
30c c H H 4-Me-Ph >375 >375 n.d. - 
31a c t-Bu H 4-OH-Ph 36.4 n.d. n.d. - 
31c c H H 4-Me-Ph >373 >373 n.d. - 
32a c t-Bu Me 4-C6H11-Ph >82.4 >82.4 n.d. - 
32c c H H 4-C6H11-Ph >96 >96 n.d. - 
Chloroquine - - - - 11±7 21±18 89±28 8.1 
a EC50 = 50% effective concentration (concentration at which 50% inhibition of CPE is observed). 
b EC90 = 90% effective concentration (concentration at which 50% inhibition of CPE is observed). 
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell). 
d The EC50, EC90 and CC50 values are the mean of at least 3 independent experiments, with standard deviations of ±10% of the 
value quoted unless otherwise stated (mean value ± standard deviations). 
e SI = the ratio of CC50 to EC50.
f Biological data as previously reported.8 
 n.d.= value could not be calculated. 
 
Considering together both antiviral activity results and cytotoxicity associated with the novel 
compounds, the small series of cyclopropyl derivatives 6-7 appears to be correlated with an overall 
activity retention, confirming what already observed to some extent for the previously reported series of 
analogues. Alkylation of this hydroxyl group to methoxy is also tolerated, suggesting that the presence 
and nature of the substituent in ring B is not relevant for the biological potential of the scaffold. In the 
acrylohydrazide series of structures (11-24), most of the antiviral potential appears to be associated with 
the presence of a tert-butyl substituent at the para position in aromatic ring A, together with an 
unsubstituted hydrazone linker and a small hydrophobic group (methyl or methoxy) at the para position 
of aromatic ring B, as indicated by the fact that the best results in terms of antiviral activity and SI index 
are achieved with 11a and 12a. Even though their selectivity index is lower in comparison with 2 (the 
least toxic compound previously identified), the CC50 values obtained for these two novel structures show 
a significantly reduced standard deviation in comparison with 2, allowing a greater confidence in the 
evaluation of their safety in cells. The antiviral activity of the scaffold seems to be simultaneously 
influenced by the nature of the two aromatic substituents, as the association of a 4-methyl substituent or 
of the original 3,4-diethoxy substituent in ring B with a smaller substituent as the 4-methyl group in ring 
A is associated with loss of antiviral activity (12b, 24b), and the same effect is obtained with an 
unsubstituted phenyl ring A (12c). Surprisingly given the structural features of 2, increasing the size of 
the 4-methyl group in 12a to an isopropyl substituent (13a) is related to a significantly increased 
cytotoxic effect, while a tert-butyl group in this position (14a) is associated with a complete loss of both 
antiviral and cytotoxic effect. Trying to investigate the effect of a methyl-substituted hydrazone linker 
and a 4-cyclohexyl substituent in ring B, previously observed as partially tolerated with 1d, 15a and 15c 
have been prepared carrying this double modification. The complete loss of activity associated with both 
these analogues suggests a different trend in antiviral effect associated with the cyclopropyl scaffold of 
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1a-e and the acrylo structure of 2. The removal of the substituent in ring B (16a) is associated with an 
increased cytotoxicity, while replacement of the para substituent in this ring with a 4-nitro (17a) or a 4-
chloro (18a) moiety led to complete loss of activity. Introduction of a 4-hydroxy group in ring B (19a), 
which was envisaged as a means to increase the polarity and therefore the water solubility of the scaffold, 
is associated with cytotoxicity, further confirming the different trend for biological effects between the 
cyclopropylic and acrylo series of compounds. Another attempt to obtain a more polar structure was 
carried out with the replacement of ring B with a pyrazine group (20a), but this modification led to a 
significant activity reduction. Insertion of an extra phenyl group at the para position of ring B in the 
unsubstituted hydrazone scaffold (22a) leads to cytotoxicity, while the same modification on the methyl-
hydrazone structure (23a) does not show the same cytotoxic effect, but is associated with complete loss 
of activity. The same effect can be observed for the presence of the substituted methyl-hydrazone linker 
and a 3,4-methoxy substitution in ring B (21a), suggesting that the presence of an unsubstituted 
hydrazone central linker is essential for antiviral activity retention in the acrylo-hydrazide family of 
structures. The replacement of the hydrazone group with a more stable and more flexible benzylamide 
(25-26) is associated with either loss of antiviral activity (25a, 25c, 26c) or with an increased cytotoxicity 
(26a). 
Except for 31a, which seems to partially retain some antiviral effect with an EC50 in the micromolar 
range, all the remaining unsaturated analogues 29-32 are associated with a complete abolishment of 
antiviral effect, suggesting that the rigidity of the scaffold and the molecular geometry given by the trans-
cyclopropane or trans-double bond are essential for the antiviral effect of these molecules. A general 
summary of the structure-activity relationships observed for the scaffold of 1 and 2 is depicted in Figure 
3. 
 
Figure 3. Summary of the antiviral structure-activity relationships obtained with this work for the antiviral scaffold of 1 and 2. 
 
2.4 Molecular modelling 
As briefly explained in the Introduction, the original hit 1 was identified as a selective antiviral agent 
against CHIKV following a docking-based virtual screening procedure of commercial compounds, with 
which the structure of the CHIKV nsP2 protease, an essential enzyme for the viral replication, had been 
chosen as target for the selection of potential inhibitors of the viral replication.8 Both hits 1 and 2 are 
predicted to exert their antiviral activity through the inhibition of this enzyme, by binding to its catalytic 
pocket. Even though a recently published study suggests that 1 is not a strong inhibitor of CHIKV nsP2 
activity in vitro,17 three of our previously reported close analogues of 1 were instead found, in the same 
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study, to inhibit the protheolitical activity of CHIKV nsP2, along with several novel closely related 
derivatives of 1, described in the same work, which all show inhibition of the CHIKV protease activity 
in the reported enzymatic assay. Due to these indications, the predicted binding to the protease active site 
was investigated for the novel compounds prepared, with the aim to possibly find a rational explanation 
for the differences in activity found for the new structures. Glide SP docking algorithm was used for all 
simulations carried out.18-19 The predicted binding to the nsP2 protease found for our original hit 2 and 
representative novel analogues 12a, 25a and 29a is shown in Figure 4.  
A)      B) 
C)      D) 
  
Figure 2. Predicted binding mode of 2 (A), 12a (B), 25a (C) and 29a (D) to the proteolitic site of CHIKV nsP2 (PDB ID 3TRK). 
 
According to our molecular modelling predictions, the hydrazyde bond of 2 (Figure 2A) fits with high 
affinity the proteolytic site of the enzyme and is involved, through its carbonyl oxygen, in a direct 
hydrogen bond with the side chain of Trp650. The two aromatic portions, even though not involved in 
direct interactions with the surrounding enzyme residues, appear important to anchor the central portion 
of the molecule in the region defined by the catalytic triad. A very similar binding mode is shared by 12a 
(Figure 2B), which retains the antiviral effect of 2 and is representative of the two first series of novel 
compounds prepared, 6, 7 and 11-24. Docking results on the CHIKV nsP2 protein catalytic pocket found 
for all the compounds in these two series (data not shown) do not reveal significant differences in their 
predicted binding mode to the enzyme active site, possibly indicating that the reason for their marked 
differences in antiviral activities might be related with cell-penetration factors or with the additional 
interaction with  different viral or host targets. A significant difference in predicted binding is instead 
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found for 25a, representative of the small amide series of compounds prepared, for which the loss of 
activity can be correlated with its increased flexibility, which does not allow an optimal fitting of the 
protein sub-site surrounding the catalytic residues, and to the overall reduced size of the molecule. The 
same negative effect associated with the increased flexibility can be speculated for 29a, where the 
saturation of the double bond in trans configuration is associated with a different occupation of the target 
site, as in most of the predicted binding poses found the hydrogen bond with Trp650 is lost in favour of 
a predicted interaction with Cys579. 
 
3. Conclusions 
Starting from the structures of two anti-CHIKV hits previously identified, different series of novel 
analogues were designed and synthesised to explore the structure-activity relationships associated with 
these antiviral agents. Different structural elements were identified as essential for antiviral properties, 
such as the presence of a tert-butyl substituent on ring B, an unsubstituted hydrazone linker and the 
overall length and rigidity of the acrylo-hydrazide scaffold, while the associated antiviral effect was 
found to follow a different trend for the two original hit scaffolds 1 and 2. Different novel antiviral agents 
with anti-CHIKV EC50 values in the low micromolar range and good selectivity indexes were identified, 
while further structural modifications are the focus of present invetsigations and will be reported in due 
course. In particular, present synthetic efforts are directed towards the insertion of the trans-double bond 
of 2 in a condensed aromatic ring, on the replacement of the central linker with more stable groups while 
maintaining the overall length of the molecule, and on the inclusion of the central hydrazone group in a 
third aromatic ring. 
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S.1 Chemistry materials and methods 
All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). 1H and 13C NMR 
spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with 
Me4Si as internal standard. Mass spectra were determined with a Bruker microTOF spectrometer using 
electrospray ionization (ESI source). For mass spectra, solutions were made in HPLC grade methanol. 
Flash column chromatography was performed with silica gel 60 (230–400mesh) (Merck) and TLC was 
carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by 
illumination under UV light (254 nm). Melting points were determined on an electrothermal instrument 
and are uncorrected. All solvents were dried prior to use and stored over 4 Å molecular sieves, under 
nitrogen. Purity of prepared compounds was determined by HPLC-UV analysis (Thermo HPLC 
connected with UV detector). All compounds tested in biological assays were >95% pure. The purity of 
all final compounds was determined to be >95% by HPLC using the eluents water (eluent A), acetonitrile 
(eluent B), at the following conditions: Varian Pursuit, 150 mm × 4.6 mm, 5.0 μm, 1.0 mL/min, 
gradient 30 min 10% → 100% eluent B in eluent A. 
Intermediates 4, 5, 9a-c, 10a-c and 27-28 were prepared according to previously reported procedures.S1-
S2 Preparation and charecterisation of all final products are detailed below. Most hydrazone final products 
show two sets of signals in NMR experiments. 
 
S.1.1 General method for the preparation of hydrazones 6, 7, 11-24, 29-32 
A mixture of the appropriate hydrazide (1 eq) and the differently substituted benzaldehyde or 
acetophenone (1.2 eq) in EtOH (8.5 ml . mmol/eq) was refluxed overnight or for 24 hours. The mixture 
was then cooled to room temperature and the precipitate formed was filtered and washed with cold EtOH 
and hexane. The solid obtained was purified by crystallization or flash column chromatography. 
 
S.1.1.1 (E)-2-(4-(tert-Butyl)phenyl)-N'-(4-methoxybenzylidene)cyclopropanecarbohydrazide (6) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 70:30 v/v. Obtained in 76% yield as a white solid. M.p. 175-179 °C. TLC (8:2 n-hexane-
EtOAc, Rf: 0.35). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 1.25 (s, 
9 H), 1.28 (s, 9H), 1.29-1.39 (m, 2H), 1.45-1.55 (m, 2H), 1.84-1.89 (m, 1H), 2.28-2.31 (m, 1H), 2.37-
2.41 (m, 1H), 2.86-2.89 (m, 1H), 3.76 (s, 3H), 3.81 (s, 3H), 6.93 (d, J= 8.4 Hz, 2H), 7.01 (d, J= 8.3 Hz, 
2H), 7.10 (d, J= 8.2 Hz, 2H), 7.12 (d, J= 8.3 Hz, 2H), 7.28-7.32 (m, 4H), 7.55 (d, J= 8.0 Hz, 2H), 7.63 
(d, J= 8.0 Hz, 2H), 7.95 (s, 1H), 8.07 (s, 1H), 11.30 (bs, 1H), 11.49 (bs, 1H). 13C-NMR (DMSO-d6), : 
14.8, 16.4, 21.5, 24.2, 24.8, 24.9, 31.1, 34.0, 55.2, 55.3, 114.2, 114.3, 125.0, 125.1, 125.5, 125.7, 126.7, 
126.8, 128.1, 128.5, 137.6, 137.7, 143.0, 145.5, 148.5, 160.4, 160.6, 167.4, 172.6. Anal. Calcd for 
C22H26N2O2: C, 75.40; H, 7.48; N, 7.99. Found: C, 75.47; H, 7.26; N, 7.84. MS [ESI, m/z]: 351.2 [M+H]. 
 
S.1.1.2 (E)-2-(4-(tert-Butyl)phenyl)-N'-(4-hydroxybenzylidene)cyclopropanecarbohydrazide (7) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 90:10 v/v. Obtained in 54% yield as a pale yellow. M.p. 198-200 °C. TLC (5:5 n-hexane-
EtOAc, Rf: 0.41). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 1.24 (s, 
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9 H), 1.27 (s, 9H), 1.30-1.44 (m, 2H), 1.46-1.50 (m, 2H), 1.80-1.85 (m, 1H), 2.23-2.28 (m, 1H), 2.36-
2.41 (m, 1H), 2.83-2.89 (m, 1H), 6.73-6.82 (m, 4H), 7.08 (d, J= 8.3 Hz, 2H), 7.11 (d, J= 8.2 Hz, 2H), 
7.27-7.31 (m, 4H), 7.46 (d, J= 8.1 Hz, 2H), 7.52 (d, J= 8.1 Hz, 2H), 7.92 (s, 1H), 8.04 (s, 1H), 9.85 (bs, 
2H), 11.22 (bs, 1H), 11.41 (bs, 1H). 13C-NMR (DMSO-d6), : 14.0, 16.3, 21.5, 24.1, 24.8, 24.9, 31.1, 
34.0, 115.6, 115.6, 125.0, 125.1, 125.2, 125.3, 125.5, 125.7, 128.3, 128.6, 137.6, 137.7, 143.4, 145.9, 
148.4, 159.0, 159.2, 167.2, 172.5. Anal. Calcd for C21H24N2O2: C, 74.97; H, 7.19; N, 8.33. Found: C, 
75.13; H, 7.31; N, 8.11. MS [ESI, m/z]: 337.2 [M+H]. 
 
S.1.1.3 (2-E)-3-(4-(tert-Butyl)phenyl)-N'-(4-methoxybenzylidene)acrylohydrazide (11a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 71% yield as an off-white solid. M.p. 186-188 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.40). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.29 (s, 9H), 1.30 (s, 9H), 3.81 (s, 6H), 6.67 (d, J= 15.7 Hz, 1H), 7.01 (d, J= 8.1 Hz, 4H), 7.44-7.48 (m, 
4H), 7.54-7.58 (m, 4H), 7.60-7.66 (m, 2H), 7.67-7.72 (m, 5H), 8.02 (s, 1H), 8.20 (s, 1H), 11.36 (bs, 1H), 
11.52 (bs, 1H).  13C-NMR (DMSO-d6), : 30.9, 34.5, 55.2, 55.3, 114.2, 116.5, 119.4, 125.7, 125.8, 126.8, 
126.9, 127.5, 127.9, 128.4, 128.6, 131.9, 132.2, 140.1, 141.6, 142.8, 146.4, 152.6, 152.7, 160.6, 160.8, 
161.4, 165.9. Anal. Calcd for C21H24N2O2: C, 74.97; H, 7.19; N, 8.33. Found: C, 74.81; H, 7.40; N, 8.42. 
MS [ESI, m/z]: 359.1 [M+Na]. 
 
S.1.1.4 (2-E)-3-(4-(tert-Butyl)phenyl)-N'-(4-methylbenzylidene)acrylohydrazide (12a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 77% yield as an off-white solid. M.p. 200-202 °C. TLC (6:4 n-
hexane-EtOAc, Rf: 0.44). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.29 (s, 9H), 1.30 (s, 9H), 2.34 (s, 6H), 6.68 (d, J= 15.8 Hz, 1H), 7.26 (d, J= 7.9 Hz, 4H), 7.43-7.49 (m, 
3H), 7.51-7.58 (m, 4H), 7.61-7.70 (m, 8H), 8.04 (s, 1H), 8.23 (s, 1H), 11.42 (bs, 1H), 11.59 (bs, 1H).  
13C-NMR (DMSO-d6), : 21.0, 30.9, 34.5, 116.4, 119.4, 125.7, 125.8, 126.8, 127.1, 127.5, 127.9, 129.4, 
131.5, 131.6, 131.9, 132.1, 139.5, 139.8, 140.2, 141.8, 143.1, 146.6, 152.6. Anal. Calcd for C21H24N2O2: 
C, 74.97; H, 7.19; N, 8.33. Found: C, 74.81; H, 7.40; N, 8.42. MS [ESI, m/z]: 359.1 [M+Na]. 
 
S.1.1.5 (2E)-N'-(4-Methylbenzylidene)-3-(p-tolyl)acrylohydrazide (12b) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 67% yield as an off-white solid. M.p. 232-234 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.32). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
2.32 (s, 6H), 2.37 (s, 6H), 6.65 (d, J= 15.7 Hz, 1H), 7.24-7.31 (m, 8H), 7.50-7.54 (m, 3H), 7.57 (d, J= 
15.7 Hz, 1H), 7.60-7.68 (m, 7H), 8.03 (s, 1H), 8.22 (s, 1H), 11.40 (bs, 1H), 11.56 (bs, 1H). 13C-NMR 
(DMSO-d6), : 20.9, 21.0, 116.1, 118.3, 119.2, 126.8, 127.0, 127.6, 127.7, 128.1, 129.3, 129.5, 131.4, 
131.6, 131.9, 132.1, 139.5, 139.6, 139.8, 139.9, 140.4, 141.9, 143.1, 146.6, 161.4, 166.0. Anal. Calcd for 
C18H18N2O: C, 77.67; H, 6.52; N, 10.06. Found: C, 77.51; H, 6.27; N, 10.24. MS [ESI, m/z]: 279.1 
[M+H]. 
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S.1.1.6 N'-(4-Methylbenzylidene)cinnamohydrazide (12c) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 71% yield as an off-white solid. M.p. 204-206 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.34). One set of signals observed in NMR experiments. 1H-NMR (CDCl3), : 2.43 
(s, 3H), 7.34-7.19 (m, 2H), 7.48-7.37 (m, 3H), 7.73-7.54 (m, 5H), 7.86 (s, 1H), 7.90 (d, J= 16.0 Hz, 1H); 
9.47 (bs, 1H).13C-NMR (CDCl3), : 21.5, 116.5, 127.2, 128.3, 128.8, 128.9, 129.5, 130.0, 131.0, 135.1, 
140.5, 143.7, 167.3. Anal. Calcd for C17H16N2O: C, 77.25; H, 6.10; N, 10.60. Found: C, 77.12; H, 6.39; 
N, 10.37. MS [ESI, m/z]: 265.1 [M+H]. 
 
S.1.1.7 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(4-isopropylbenzylidene)acrylohydrazide (13a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 77% yield as an off-white solid. M.p. 223-225 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.55). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.22 (d, J= 6.8 Hz, 12H), 1.29 (s, 9H), 1.30 (s, 9H), 3.01-2.85 (m, 2H), 6.68 (d, J= 15.8 Hz, 1H), 7.29-
7.35 (m, 4H), 7.43-7.50 (m, 4H), 7.52-7.64 (m, 5H), 7.65-7.72 (m, 6H), 8.05 (s, 1H), 8.24 (s, 1H), 11.43 
(s, 1H), 11.59 (s, 1H). 13C-NMR (DMSO-d6), : 23.6, 30.9, 33.3, 33.4, 34.5, 116.4, 119.3, 125.7, 125.7, 
126.7, 126.9, 127.1, 127.5, 127.9, 131.9, 132.0, 132.1, 140.2, 141.7, 143.0, 146.5, 150.2, 150.6, 152.6, 
152.7, 161.4, 166.0. Anal. Calcd for C23H22N2O: C, 77.27; H, 8.10; N, 8.04. Found: C, 77.49; H, 8.25; 
N, 7.87. MS [ESI, m/z]: 349.2 [M+H]. 
 
S.1.1.8 (2E)-N'-(4-(tert-Butyl)benzylidene)-3-(4-(tert-butyl)phenyl)acrylohydrazide (14a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 68% yield as an off-white solid. M.p. 223-225 °C. TLC (6:4 n-
hexane-EtOAc, Rf: 0.52). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.29 (s, 18H), 1.31 (s, 18H), 6.69 (d, J= 15.7 Hz, 1H), 7.39-7.50 (m, 7H), 7.52-7.58 (m, 3H), 7.58-7.62 
(m, 2H), 7.62-7.71 (m, 7H), 8.05 (s, 1H), 8.25 (s, 1H), 11.46 (bs, 1H), 11.60 (bs, 1H). 13C-NMR (DMSO-
d6), : 30.8, 30.9, 31.0, 31.2, 34.5, 116.4, 119.3, 125.5, 125.6, 125.7, 126.6, 126.9, 127.5, 127.9, 131.5, 
131.9, 132.1, 140.3, 141.7, 142.8, 146.5, 152.4, 152.6, 152.7, 161.5, 166.0. Anal. Calcd for C24H30N2O: 
C, 79.52; H, 8.34; N, 7.73. Found: C, 79.45; H, 8.51; N, 7.87. MS [ESI, m/z]: 363.2 [M+H]. 
 
S.1.1.9 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(1-(4-cyclohexylphenyl)ethylidene)acrylohydrazide (15a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 65% yield as a pale yellow solid. M.p. 258-260 °C. TLC (6:4 n-
hexane-EtOAc, Rf: 0.45). One set of signals observed in NMR experiments. 1H-NMR (CDCl3), : 1.35-
1.30 (m, 2H), 1.38 (s, 9H), 1.47-1.45 (m, 4H), 2.32 (s, 3H), 2.66-2.51 (m, 1H), 7.31 (d, J= 8.3 Hz, 2H), 
7.46 (d, J= 8.5 Hz, 2H), 7.60-7.65 (m, 3H), 7.76 (d, J= 8.3, 2H), 7.89 (d, J= 15.9 Hz, 1H), 9.10 (bs, 1H, 
NH).13C-NMR (CDCl3), : 12.8, 26.1, 26.8, 31.1, 34.3, 34.9, 44.4, 116.0, 125.8, 126.2, 126.6, 127.0, 
128.2, 132.6, 135.8, 147.3, 149.6, 153.5, 167.9. Anal. Calcd for C27H34N2O: C, 80.55; H, 8.51; N, 6.96. 
Found: C, 80.66; H, 8.37; N, 7.13. MS [ESI, m/z]: 403.3 [M+H]. 
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S.1.1.10 (1-(4-Cyclohexylphenyl)ethylidene)cinnamohydrazide (15c) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 69% yield as a pale yellow solid. M.p. 240-242 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.40). One set of signals observed in NMR experiments. 1H-NMR (CDCl3), : 1.36-
1.26 (m, 1H), 1.54-1.38 (m, 4H, ), 1.80 (m, 1H), 1.99-1.84 (m, 4H), 2.31 (s, 3H), 2.64-2.53 (m, 1H), 7.31 
(d, J= 8.1 Hz, 2H), 7.47-7.40 (m, 3H), 7.70-7.63 (m, 3H), 7.75 (d, J= 8.1, 2H), 7.89 (d, J= 15.8 Hz, 1H), 
8.91 (s, 1H, NH). 13C-NMR (CDCl3), : 26.1, 26.8, 34.3, 44.4, 116.8, 126.2, 127.0, 128.3, 128.8, 130.0, 
132.2, 135.6, 143.7, 149.4, 149.7, 167.5. Anal. Calcd for C23H26N2O: C, 79.73; H, 7.56; N, 8.09. Found: 
C, 79.49; H, 7.41; N, 8.30. MS [ESI, m/z]: 347.2 [M+H]. 
 
S.1.1.11 (2E)-N'-Benzylidene-3-(4-(tert-butyl)phenyl)acrylohydrazide (16a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 73% yield as an off-white solid. M.p. 227-229 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.45). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.29 (s, 9H), 1.30 (s, 9H), 6.68 (d, J= 15.7 Hz, 1H), 7.41-7.48 (m, 10H), 7.54-7.59 (m, 3H), 7.62 (d, J= 
15.7, 1H), 7.65-7.70 (m, 3H), 7.72-7.78 (m, 4H),  8.08 (s, 1H), 8.27 (s, 1H), 11.49 (bs, 1H), 11.66 (bs, 
1H). 13C-NMR (DMSO-d6), : 30.9, 34.53, 116.3, 119.2, 125.7, 125.8, 126.8, 127.0, 127.5, 127.9, 128.7, 
129.7, 129.9, 131.9, 132.1, 134.2, 134.3, 140.4, 141.9, 143.0, 146.6, 152.7, 152.8, 161.6, 166.1. Anal. 
Calcd for C20H22N2O: C, 78.40; H, 7.24; N, 9.14. Found: C, 78.67; H, 6.99; N, 8.88. MS [ESI, m/z]: 
307.2 [M+H]. 
 
S.1.1.12 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(4-nitrobenzylidene)acrylohydrazide (17a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 70% yield as a pale yellow solid. M.p. 230-232 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.35). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.30 (s, 18H), 6.68 (d, J= 15.7 Hz, 1H), 7.41-7.48 (m, 4H), 7.53-7.60 (m, 3H), 7.73-7.81 (m, 4H), 7.88-
8.07 (m, 4H), 8.16 (s, 1H), 8.24-8.31 (m, 4H), 8.36 (s, 1H), 11.79 (bs, 1H), 11.94 (bs, 1H). 13C-NMR 
(DMSO-d6), : 30.9, 34.5, 115.9, 118.91, 123.9, 125.6, 125.7, 125.8, 127.7, 127.8, 127.9, 128.1, 131.8, 
132.0, 140.5, 140.6, 140.7, 141.1, 142.6, 144.0, 147.6, 147.7, 152.9, 153.0, 161.9, 166.5. Anal. Calcd for 
C20H21N3O3: C, 68.36; H, 6.02; N, 11.96. Found: C, 68.12; H, 5.89; N, 12.21. MS [ESI, m/z]: 352.2 
[M+H]. 
 
S.1.1.13 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(1-(4-chlorophenyl)ethylidene)acrylohydrazide (18a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 72% yield as an off-white solid. M.p. 244-246 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.41). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.30 (s, 18H), 2.30 (s, 3H), 2.33 (s, 3H), 7.02 (d, J= 15.6 Hz, 1H), 7.45-7.51 (m, 8H), 7.53-7.60 (m, 4H), 
7.63-7.71 (m, 3H), 7.80-7.95 (m, 4H), 10.62 (bs, 1H), 10.67 (bs, 1H). 13C-NMR (DMSO-d6), : 13.5, 
13.9, 30.9, 34.5, 116.6, 119.7, 125.7, 127.4, 127.5,127.8, 127.9, 128.1, 128.3, 132.1, 133.8, 137.0, 140.3, 
142.0, 152.6. Anal. Calcd for C21H23ClN2O: C, 71.07; H, 6.53; N, 7.89. Found: C, 71.15; H, 6.50; N, 
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8.02. MS [ESI, m/z]: 355.2, 357.2 [M+H]. 
 
S.1.1.14 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(4-hydroxybenzylidene)acrylohydrazide (19a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 0:100 v/v. Obtained in 69% yield as a pale yellow solid. M.p. 268-270 °C. TLC (3:7 n-
hexane-EtOAc, Rf: 0.30). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.29 (s, 9H), 1.30 (s, 9H), 6.66 (d, J= 16.0 Hz, 1H), 6.82-6.86 (m, 4H), 7.43-7.48 (m, 5H), 7.53-7.60 (m, 
7H), 7.62-7.69 (m, 3H), 7.97 (s, 1H), 8.15 (s, 1H), 9.87 (bs, 1H), 9.91 (bs, 1H), 11.28 (bs, 1H), 11.45 
(bs, 1H). 13C-NMR (DMSO-d6), : 30.9, 34.5, 115.6, 116.6, 118.5, 119.5, 125.2, 125.3, 125.7, 125.8, 
127.4, 127.9, 128.5, 128.8, 131.9, 132.2, 139.9, 141.4, 143.2, 146.8, 152.5, 152.7, 159.1, 159.3, 161.2, 
165.8. Anal. Calcd for C20H22N2O2: C, 74.51; H, 6.88; N, 8.69. Found: C, 74.62; H, 6.59; N, 8.54. MS 
[ESI, m/z]: 323.2 [M+H]. 
 
S.1.1.15 (2E)-3-(4-(tert-Butyl)phenyl)-N'-(1-(pyrazin-2-yl)ethylidene)acrylohydrazide (20a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 0:100 v/v. Obtained in 74% yield as an off-white solid. M.p. 230-232 °C. TLC (4:6 n-
hexane-EtOAc, Rf: 0.28). Two sets of signals observed in NMR experiments. 1H-NMR (CDCl3), : 1.31 
(s, 9H), 1.37 (s, 9H), 2.46 (s, 6H), 6.94 (d, J= 15.7 Hz, 1H), 7.33 (d, J= 8.4 Hz, 2H), 7.41-7.49 (m, 3H), 
7.52 (d, J= 8.4, 2H), 7.57-7.69 (m, 4H), 7.76 (d, J= 15.7, 1H), 7.93 (d, J= 15.7, 1H), 8.56 (apparent s, 
3H), 9.29 (s, 1H), 9.45 (bs, 1H), 10.98 (bs, 1H). 13C-NMR (CDCl3), : 10.4, 31.1, 34.8, 115.0, 117.2, 
125.8, 127.8, 128.2, 132.0, 132.2, 141.6, 142.8, 143.0, 143.7, 144.7, 146.3, 150.6, 153.9, 161.1, 167.8. 
Anal. Calcd for C19H22N4O: C, 70.78; H, 6.88; N, 17.38. Found: C, 70.94; H, 6.61; N, 17.42. MS [ESI, 
m/z]: 323.2 [M+H]. 
 
S.1.1.16 (2E)-3-(4-(tert-butyl)phenyl)-N'-(1-(3,4-dimethoxyphenyl)ethylidene)acrylohydrazide (21a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 40:60 v/v. Obtained in 75% yield as a pale yellow solid. M.p. 200-202 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.23). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.30 (s, 18H), 2.28 (s, 3H), 2.32 (s, 3H), 3.80 (s, 6H), 3.81 (s, 3H), 3.87 (s, 3H), 6.97-7.04 (m, 3H), 7.32-
7.38 (m, 2H), 7.41-7.50 (m, 6H), 7.52-7.61 (m, 4H), 7.62-7.68 (m, 3H), 10.50 (bs, 1H), 10.58 (bs, 1H). 
13C-NMR (DMSO-d6), : 13.3, 14.1, 30.9, 34.5, 55.3, 55.5, 108.9, 109.4, 111.1, 111.2, 117.0, 118.5, 
119.1, 119.7, 120.0, 125.7, 127.4, 127.7, 130.8, 132.2, 139.8, 141.4, 147.2, 148.4, 149.9, 150.1, 151.7, 
152.5, 152.5, 161.8, 163.2. Anal. Calcd for C20H22N2O2: C, 74.51; H, 6.88; N, 8.69. Found: C, 74.62; H, 
6.59; N, 8.54. MS [ESI, m/z]: 323.2 [M+H]. 
 
S.1.1.17 (2E)-N'-([1,1'-Biphenyl]-4-ylmethylene)-3-(4-(tert-butyl)phenyl)acrylohydrazide (22a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 65% yield as a pale yellow solid. M.p. 218-220 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.30). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.30 (s, 9H), 1.31 (s, 9H), 6.69 (d, J= 15.7 Hz, 1H), 7.38-7.43 (m, 2H), 7.46-7.52 (m, 8H), 7.56-7.61 (m, 
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4H), 7.63-7.71 (m, 3H), 7.72-7.75 (m, 4H), 7.76-7.80 (m, 4H), 7.82-7.87 (m, 4H), 8.11 (s, 1H), 8.30 (s, 
1H), 11.52 (bs, 1H), 11.68 (bs, 1H). 13C-NMR (DMSO-d6), : 30.9, 34.5, 116.4, 119.3, 125.7, 125.8, 
126.6, 126.9, 127.4, 127.5, 127.6, 127.8, 128.0, 129.0, 139.3, 140.4, 141.3, 141.5, 141.9, 142.6, 146.1, 
152.7, 152.8, 160.3, 161.5, 166.2. Anal. Calcd for C26H26N2O: C, 81.64; H, 6.85; N, 7.32. Found: C, 
81.51; H, 6.99; N, 7.14. MS [ESI, m/z]: 383.2 [M+H]. 
 
S.1.1.18 (2E)-N'-(1-([1,1'-Biphenyl]-4-yl)ethylidene)-3-(4-(tert-butyl)phenyl)acrylohydrazide (23a) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 68% yield as an off-white solid. M.p. 254-256 °C. TLC (6:4 n-
hexane-EtOAc, Rf: 0.30). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), : 
1.31 (s, 18H), 2.34 (s, 3H), 2.37 (s, 3H), 7.04 (d, J= 15.7 Hz, 1H), 7.39-7.44 (m, 2H), 7.47-7.52 (m, 8H), 
7.57-7.60 (m, 3H), 7.62-7.69 (m, 4H), 7.72-7.78 (m, 8H), 7.92-7.96 (m, 4H), 10.60 (bs, 1H), 10.68 (bs, 
1H). 13C-NMR (DMSO-d6), : 14.6, 30.9, 34.5, 117.6, 119.8, 125.8, 126.4, 126.5, 126.9, 127.5, 127.7, 
127.9, 128.9, 137.2, 139.2, 140.1, 140.5, 141.3, 142.5, 144.9, 145.7, 146.5, 147.6, 161.4, 164.9, 166.2. 
Anal. Calcd for C27H28N2O: C, 81.78; H, 7.12; N, 7.06. Found: C, 81.99; H, 7.35; N, 6.84. MS [ESI, 
m/z]: 397.2 [M+H]. 
 
S.1.1.19 (2E)-N'-(3,4-Diethoxybenzylidene)-3-(p-tolyl)acrylohydrazide (24c) 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100:0 v/v increasing to n-
hexane-EtOAc 50:50 v/v. Obtained in 66% yield as a pale yellow solid. M.p. 170-172 °C. TLC (5:5 n-
hexane-EtOAc, Rf: 0.30). Two sets of signals observed in NMR experiments. 1H-NMR (CDCl3), : 1.33-
1.48 (m, 6H), 1.48-1.59 (m, 6H), 2.37 (s, 3H), 2.42 (s, 3H), 4.06-4.13 (m, 4H), 4.17 (q, J= 6.9 Hz, 2H), 
4.22 (q, J= 6.9 Hz, 2H), 6.48 (d, J= 15.5 Hz, 1H), 6.80 (d, J= 6.9 Hz, 1H), 6.93 (d, J= 8.0 Hz, 1H), 7.01-
7.11 (m, 3H), 7.34-7.42 (m, 3H), 7.55-7.64 (m, 3H), 7.87 (s, 1H), 7.89 (s, 2H), 8.15 (s, 1H), 9.34 (bs, 
1H), 9.99 (bs, 1H). 13C-NMR (CDCl3), : 14.7, 14.8, 21.5, 64.5, 64.7, 111.1, 112.7, 115.7, 121.6, 126.7, 
128.3, 129.6, 132.5, 140.4, 143.5, 143.9, 148.9, 150.8, 167.7. Anal. Calcd for C21H24N2O3: C, 71.57; H, 
6.86; N, 7.95. Found: C, 71.33; H, 6.99; N, 8.04. MS [ESI, m/z]: 353.2 [M+H]. 
 
S.1.1.20 3-(4-(tert-Butyl)phenyl)-N'-(3,4-diethoxybenzylidene)propanehydrazide (29a) 
Purified by crystallization from EtOH. Obtained in 79% yield as a white solid. M.p. 108-112 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.61). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-
d6), : 1.25 (s, 9H), 1.26 (s, 9H), 1.31-1.37 (m, 12H), 2.46-2.49 (m, 2H), 2.83-2.89 (m, 6H), 4.02-4.08 
(m, 8H), 6.96-7.00 (m, 2H), 7.10-7.14 (m, 2H), 7.15 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 7.24 
(d, J = 1.8 Hz, 1H), 7.26 (d, J = 1.8 Hz, 1H), 7.27-7.31 (m, 4H), 7.87 (s, 1H), 8.04 (s, 1H), 11.16 (bs, 
1H), 11.23 (bs, 1H). 13C-NMR (DMSO-d6), : 14.6, 14.7, 31.2, 29.7, 33.9, 63.6, 63.7, 109.6, 112.5, 
120.7, 121.5, 124.9, 127.8, 142.6, 146.0, 126.9, 137.9, 148.1, 149.7, 167.5, 173.3. Anal. Calcd for 
C24H32N2O3: C, 72.70; H, 8.13; N, 7.06. Found: C, 72.95; H, 8.17; N, 6.88. MS [ESI, m/z]: 397.1 [M+H]. 
 
S.1.1.21 N'-(3,4-Diethoxybenzylidene)-3-phenylpropanehydrazide (29c) 
Purified by crystallization from EtOH. Obtained in 77% yield as a white solid. M.p. 94-98 °C. TLC (3:7 
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n-hexane-EtOAc, Rf: 0.72). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), 
: 1.31-1.36 (m, 12H), 2.52-2.55 (m, 2H), 2.87-2.92 (m, 6H), 4.01-4.08 (m, 8H), 6.96-7.00 (m, 2H), 
7.10-7.14 (m, 2H), 7.16-7.21 (m, 2H), 7.23-7.25 (m, 3H), 7.26-7.31 (m, 7H), 7.88 (s, 1H), 8.04 (s, 1H), 
11.17 (bs, 1H), 11.24 (bs, 1H). 13C-NMR (DMSO-d6), : 14.6, 14.7, 30.1, 30.7, 33.8, 35.7, 109.7, 112.6, 
120.7, 121.5, 125.8, 125.9, 126.8, 142.7, 146.1, 126.9, 141.0, 148.2, 149.9, 173.2. Anal. Calcd for 
C20H24N2O3: C, 70.56; H, 7.11; N, 8.23. Found: C, 70.69; H, 7.33; N, 8.05. MS [ESI, m/z]: 341.0 [M+H]. 
 
S.1.1.22 3-(4-(tert-Butyl)phenyl)-N'-(4-methylbenzylidene)propanehydrazide (30a) 
Purified by crystallization from EtOH. Obtained in 81% yield as a white solid. M.p. 113-115 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.66). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-
d6), : 1.33 (s, 18H), 2.39 (s, 3H), 2.41 (s, 3H), 2.60-2.64 (m, 2H), 3.04-3.08 (m, 4H), 3.10-3.14 (m, 2H), 
7.19-7.20 (m, 2H), 7.23 (d, J = 8.1 Hz, 4H), 7.26 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 4H), 7.57 (d, J 
= 8.1 Hz, 4H), 7.62 (d, J = 8.1 Hz, 2H), 7.79 (s, 1H), 7.96 (s, 1H), 8.48 (bs, 1H), 9.73 (bs, 1H). 13C-NMR 
(DMSO-d6), : 21.5, 31.0, 30.2, 34.6, 34.4, 125.3, 125.5, 127.1, 127.6, 143.7, 128.1, 138.1, 140.4, 148.9, 
175.4. Anal. Calcd for C21H26N2O: C, 78.22; H, 8.13; N, 8.69. Found: C, 77.97; H, 8.26; N, 8.88. MS 
[ESI, m/z]: 323.1 [M+H]. 
 
S.1.1.23 N'-(4-Methylbenzylidene)-3-phenylpropanehydrazide (30c) 
Purified by crystallization from EtOH. Obtained in 92% yield as a white solid. M.p. 91-95 °C. TLC (3:7 
n-hexane-EtOAc, Rf: 0.65). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-d6), 
: 2.32 (s, 3H), 2.33 (s, 3H), 2.52-2.53 (m, 2H), 2.88-2.95 (m, 6H), 7.16-7.20 (m, 2H), 7.21-7.26 (m, 
6H), 7.27-7.31 (m, 6H), 7.52 (d, J = 7.9 Hz, 2H), 7.56 (d, J = 7.8 Hz, 2H), 7.95 (s, 1H), 8.10 (s, 1H), 
11.22 (bs, 1H), 11.31 (bs, 1H). 13C-NMR (DMSO-d6), : 20.9, 29.9, 33.7, 125.8, 126.5, 126.9, 128.2, 
128.3, 129.3, 129.4, 145.8, 131.5, 139.3, 141.0, 173.3. Anal. Calcd for C17H18N2O: C, 76.66; H, 6.81; N, 
10.52. Found: C, 76.43; H, 6.59; N, 10.74. MS [ESI, m/z]: 267.0 [M+H]. 
 
S.1.1.24 3-(4-(tert-butyl)phenyl)-N'-(4-hydroxybenzylidene)propanehydrazide (31a) 
Purified by crystallization from EtOH. Obtained in 95% yield as a white solid. M.p. 165-169 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.51). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-
d6), : 1.25 (s, 18H), 2.47 (t, J = 7.6 Hz, 2H), 2.83-2.91 (m, 6H), 6.78-6.82 (m, 4H, 7.15 (d, J = 8.1Hz, 
2H), 7.18 (d, J = 8.1 Hz, 2H), 7.28-7.31 (m, 4H), 7.46 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.86 
(s, 1H), 8.03 (s, 1H), 9.88 (bs, 2H), 11.06 (bs, 1H), 11.16 (bs, 1H). 13C-NMR (DMSO-d6), : 29.5, 33.7, 
31.2, 35.7, 115.7, 127.9, 128.2, 128.6, 146.1, 124.9, 137.9, 148.1, 159.2, 173.1. Anal. Calcd for 
C20H24N2O2: C, 74.04; H, 7.46; N, 8.64. Found: C, 73.85; H, 7.71; N, 8.47. MS [ESI, m/z]: 325.0 [M+H]. 
 
S.1.1.25 N'-(4-hydroxybenzylidene)-3-phenylpropanehydrazide (31c) 
Purified by crystallization from EtOH. Obtained in 88% yield as a white solid. M.p. 135-139 °C. TLC 
(3:7 n-hexane-EtOAc, Rf: 0.60). Two sets of signals observed in NMR experiments. 1H-NMR (DMSO-
d6), : 2.53-2.62 (m, 2H), 2.86-2.95 (m, 6H), 6.78-6.83 (m, 4H), 7.16-7.21 (m, 2H), 7.22-7.31 (m, 8H), 
7.46 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 7.87 (s, 1H), 8.02 (s, 1H), 9.88 (bs, 2H), 11.08 (bs, 
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1H), 11.16 (bs, 1H). 13C-NMR (DMSO-d6), : 30.0, 33.7, 115.5, 115.6, 125.8, 125.9, 128.2, 128.3, 128.4, 
128.7, 142.8, 146.1, 125.2, 141.4, 159.2, 173.1. Anal. Calcd for C16H16N2O2: C, 71.62; H, 6.01; N, 10.44. 
Found: C, 71.90; H, 5.98; N, 10.35. MS [ESI, m/z]: 269.0 [M+H]. 
 
S.1.1.26 3-(4-(tert-Butyl)phenyl)-N'-(1-(4-cyclohexylphenyl)ethylidene)propanehydrazide (32a) 
Purified by crystallization from EtOH. Obtained in 86% yield as a white solid. M.p. 142-144 °C. TLC 
(7:3 n-hexane-EtOAc, Rf: 0.66). One set of signals observed in NMR experiments. 1H-NMR (CDCl3), 
: 1.33 (s, 9H), 1.41-1.47 (m, 4H), 1.59-1.61 (m, 1H), 1.76-1.81 (m, 1H), 1.86-1.91 (m, 4H), 2.20 (s, 
3H), 2.53-2.58 (m, 1H), 3.04-3.08 (m, 2H), 3.10-3.14 (m, 2H), 7.23-7.27 (m, 4H), 7.35 (d, J = 6.7 Hz, 
2H), 7.68 (d, J = 6.9 Hz, 2H), 8.55 (bs, 1H). 13C-NMR (CDCl3), : 12.4, 21.4, 26.1, 26.8, 34.3, 34.7, 
30.1, 44.3, 125.3, 126.1, 126.9, 128.1, 135.4, 138.2, 146.7, 148.8, 149.6, 175.1. Anal. Calcd for 
C27H36N2O: C, 80.15; H, 8.97; N, 6.92. Found: C, 79.93; H, 9.15; N, 6.97. MS [ESI, m/z]: 405.2 [M+H]. 
 
S.1.1.27 N'-(1-(4-Cyclohexylphenyl)ethylidene)-3-phenylpropanehydrazide (32c) 
Purified by crystallization from EtOH. Obtained in 90% yield as a white solid. M.p. 119-121 °C. TLC 
(6:4 n-hexane-EtOAc, Rf: 0.61). One set of signals observed in NMR experiments. 1H-NMR (DMSO-
d6), : 1.18-1.27 (m, 2H), 1.31-1.44 (m, 6H), 1.67-1.73 (m, 4H), 1.74-1.81 (m, 8H), 2.20 (s, 6H), 2.46-
2.48 (m, 2H), 2.62-2.66 (m, 2H), 2.88-2.93 (m, 4H), 2.94-2.98 (m, 2H), 7.16-7.21 (m, 2H), 7.22-7.31 
(m, 12H), 7.65 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 10.27 (bs, 1H), 10.43 (bs, 1H). 13C-NMR 
(DMSO-d6), : 13.4, 25.5, 26.3, 30.0, 30.8, 33.7, 34.3, 35.5, 43.4, 125.8, 125.9, 126.2, 126.5, 126.6, 
128.2, 128.3, 141.1, 147.1, 148.7, 174.2. Anal. Calcd for C23H28N2O: C, 79.27; H, 8.10; N, 8.04. Found: 
C, 79.41; H, 8.02; N, 7.91. MS [ESI, m/z]: 349.1 [M+H]. 
 
S.1.2 General method for the preparation of amides 25, 26 
A mixture of the appropriate acid 9a or 9c (1 eq) and TBTU (1.2 eq.) was suspended in anhydrous THF 
(5 ml . mmol/eq.) at r.t. under a N2 atmosphere. DiPEA (2.5 eq.) was then added to the reaction, followed 
by the appropriate benzyl amine (1 eq.). The reaction was stirred at r.t. for 4-8 hours (monitored by 
T.L.C.), then diluted with EtOAc (50 ml . mmol/eq). The organic phase was washed with 0.5M aq. citric 
acid solution (2x 30 ml . mmol/eq), sat. aq. NaHCO3 solution (2x 30 ml . mmol/eq), and finally with brine 
(30 ml . mmol/eq). The organic layer was dried over Na2SO4 concentrated under vacuum. The solid 
obtained was purified by crystallization or flash column chromatography. 
 
S.1.2.1 (E)-3-(4-(tert-Butyl)phenyl)-N-(4-(trifluoromethyl)benzyl)acrylamide (25a) 
Purified by crystallisation from MeOH. Obtained in 67% yield as a white solid. M.p. 150-154 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.72). 1H-NMR (CDCl3), : 1.34 (s, 9H), 4.64 (d, J= 5.9 Hz, 2H), 6.15 (t, J= 
5.9 Hz, 1H), 6.44 (d, J= 15.5 Hz, 1H), 7.40 (d, J= 8.4 Hz, 2H), 7.44-7.47 (m, 4H), 7.61 (d, J= 8.1 Hz, 
2H), 7.69 (d, J= 15.5 Hz, 1H). 13C-NMR (CDCl3), : 31.1, 34.8, 43.2, 119.1, 125.5, 125.7, 126.8, 127.7, 
127.9, 129.6, 129.9, 131.8, 141.8, 142.4, 166.2. Anal. Calcd for C21H22F3NO: C, 69.79; H, 6.14; N, 3.88. 
Found: C, 69.60; H, 5.97; N, 4.03. MS [ESI, m/z]: 384.1 [M+Na]. 
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S.1.2.2 N-(4-(Trifluoromethyl)benzyl)cinnamamide (25c) 
Purified by crystallisation from MeOH. Obtained in 86% yield as a white solid. M.p. 130-132 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.69). 1H-NMR (CDCl3), : 4.63 (d, J= 5.9 Hz, 2H), 6.28 (t, J= 5.9 Hz, 1H), 
6.48 (d, J= 15.6 Hz, 1H), 7.36-7.38 (m, 3H), 7.44 (d, J= 8.1 Hz, 2H), 7.48-7.51 (m, 2H), 7.58 (d, J= 8.1 
Hz), 7.70 (d, J= 15.6 Hz, 1H). 13C-NMR (CDCl3), : 43.2, 120.0, 123.0, 125.5, 125.6, 125.7, 127.9, 
128.8, 129.9, 134.6, 141.9, 142.4, 166.0. Anal. Calcd for C17H14F3NO: C, 66.88; H, 4.62; N, 4.59. Found: 
C, 67.02; H, 4.55; N, 4.37. MS [ESI, m/z]: 306.1 [M+H]. 
S.1.2.3 (E)-N-([1,1'-Biphenyl]-4-ylmethyl)-3-(4-(tert-butyl)phenyl)acrylamide (26a) 
Purified by crystallisation from MeOH. Obtained in 94% yield as a white solid. M.p. 140-144 °C. TLC 
(5:5 n-hexane-EtOAc, Rf: 0.79). 1H-NMR (CDCl3), : 1.35 (s, 9H), 4.64 (d, J= 5.7 Hz, 2H), 5.97 (t, J= 
5.7 Hz, 1H), 6.42 (d, J= 15.5 Hz, 1H), 7.37 (m, 1H), 7.40-7.45 (m, 4H), 7.45-7.48 (m, 4H), 7.58-7.61 (m, 
4H), 7.70 (d, J= 15.5 Hz, 1H). 13C-NMR (CDCl3), : 31.1, 35.2, 43.5, 119.5, 125.8, 127.1, 127.3, 127.5, 
127.6, 128.4, 128.8, 132.0, 137.3, 140.6, 140.7, 141.3, 153.2, 166.0. Anal. Calcd for C26H27NO: C, 84.51; 
H, 7.37; N, 3.79. Found: C, 84.77; H, 7.41; N, 3.65. MS [ESI, m/z]: 392.2 [M+Na]. 
 
S.1.2.4 N-([1,1'-Biphenyl]-4-ylmethyl)cinnamamide (26c) 
Purified by crystallisation from MeOH. Obtained in 83% yield as a white solid. M.p. 162-166 °C. TLC 
(6:4 n-hexane-EtOAc, Rf: 0.48). 1H-NMR (CDCl3), : 4.65 (d, J= 5.8 Hz, 2H), 5.96 (t, J= 5.8 Hz, 1H), 
7.37-7.40 (m, 4H), 7.43 (d, J= 8.2 Hz, 2H), 7.44-7.48 (m, 2H), 7.45 (d, J= 15.6 Hz, 1H), 7.52-7.54 (m, 
2H), 7.59-7.61 (m, 4H), 7.72 (d, J= 15.6 Hz, 1H). 13C-NMR (CDCl3), : 43.6, 120.3, 127.1, 127.3, 127.5, 
127.8, 128.4, 128.8, 128.9, 129.7, 134.8, 137.2, 140.6, 140.7, 141.5, 165.7. Anal. Calcd for C22H19NO: 
C, 84.31; H, 6.11; N, 4.47. Found: C, 84.15; H, 5.87; N, 4.51. MS [ESI, m/z]: 314.2 [M+H]. 
 
S.2 Molecular Modelling 
All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon running Ubuntu 14.04. 
CHIKV nsP2 protease crystal structure was downloaded from the PDB data bank (http://www.rcsb.org/; 
PDB code 3TRK). Hydrogen atoms were added to the protein, using the Protonate 3D routine of the 
Molecular Operating Environment (MOE2015.10).S3 Ligand structures were built with MOE and 
minimized using the MMFF94x force field until a RMSD gradient of 0.05 kcal mol_1 was reached. The 
Maestro LigPrep toolS4 was used to prepare the ligands using the default settings, whereas the protein 
was prepared using the preparation wizard tool.S5 The docking simulations were performed using 
Maestro Glide SP using the default parameters.S6 
 
S.3 Virus cell-based CPE reduction assay 
Chikungunya virus, Indian Ocean strain 889, isolated in 2006, was cultured on African green monkey 
kidney (Vero) cells (ATCC CCL-81) in minimum essential medium MEM Rega3 (Invitrogen, Belgium) 
supplemented with 10% Foetal Bovine Serum (FBS; Integro, The Netherlands), 1% L-glutamine and 1% 
sodium bicarbonate (Invitrogen). Antiviral assays were performed in MEM Rega-3 medium 
supplemented with 2% FBS. 
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Vero cells were seeded in 96-well tissue culture plates (Becton Dickinson Falcon 96-Well Cell Culture 
Plate) at a density of 2.5 x 104 cells/well in 100 µl assay medium and were allowed to adhere overnight 
in an incubator (37 °C, 5% CO2, 95-99% RH). Next, a compound dilution series was added after which 
the cultures were infected with 0.01 MOI of CHIKV 899 in 100 µl assay medium and returned to the 
incubator. Each assay was performed in multiplicate in the same test and assays were repeated 
independently. On day 5 post-infection (p.i.), the cell viability in each assay well was measured using 
the MTS/PMS method as described by the manufacturer (Promega, The Netherlands). Chloroquine was 
included in the assay as a reference compound.S7 The 50% effective concentration (EC50) is defined as 
the compound concentration that is required to inhibit virus-induced cytopathogenic effect (CPE) by 50% 
and was determined using logarithmic interpolation employing a custom-designed database-coupled 
interface (Accelrys, United Kingdom). The anti-metabolic effect of the compounds was evaluated in 
uninfected, compound-treated cells, also by means of the MTS/PMS method. The 50% 
cytostatic/cytotoxic concentration (CC50) is defined to be the concentration of compound that reduces 
the overall metabolic activity of the uninfected, compound-treated cells by 50%, and was calculated using 
logarithmic interpolation. All assay wells were checked microscopically for minor signs of virus-induced 
CPE or alterations of the cell or monolayer morphology. 
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